Compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic inflammation of AECOPD

Pulmonary Pharmacology and Therapeutics

Volumn 31, Issue , 2015, Pages 111-116

  Sun, Xuejiao ^a,b   He, Zhiyi ^a   Zhang, Jianquan ^a   Deng, Jingmin ^a   Bai, Jing ^a   Li, Meihua ^a   Zhong, Xiaoning ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b LIUZHOU PEOPLE S HOSPITAL   (China)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Inhaled corticosteroid; Safety

Indexed keywords

BUDESONIDE; C REACTIVE PROTEIN; HISTONE DEACETYLASE 2; INTERLEUKIN 8; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACETATE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BLOOD; BLOOD GAS ANALYSIS; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; INSOMNIA; LUNG FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STOMACH PAIN; WESTERN BLOTTING; AGED; COMPARATIVE STUDY; DRUG ADMINISTRATION ROUTE; DRUG COMBINATION; IMMUNOLOGY; INFLAMMATION; LUNG FUNCTION TEST; METABOLISM; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

AGED; ANTI-INFLAMMATORY AGENTS; BLOOD GAS ANALYSIS; BUDESONIDE; C-REACTIVE PROTEIN; DRUG ADMINISTRATION ROUTES; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-8; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84926417891     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2014.09.004     Document Type: Article

References (20)

1. Barnes P.J. Chronic obstructive pulmonary disease. NEngl J Med 2000, 343:269-280.
2. Hogg J.C., Chu F., Utokaparch S., Woods R., Elliott W.M., Buzatu L., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. NEngl J Med 2004, 350:2645-2653.
3. Asia Pacific COPD Roundtable Group Global initiative for chronic obstructive lung disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective. Respirology 2005, 10:9-17.
4. Lamela J., Vega F. Immunologic aspects of chronic obstructive pulmonary disease. NEngl J Med 2009, 361:1024.
5. Han M.K., Agusti A., Calverley P.M., Celli B.R., Criner G., Curtis J.L., et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010, 182:598-604.
6. Donaldson G.C., Hurst J.R., Smith C.J., Hubbard R.B., Wedzicha J.A. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010, 137:1091-1097.
7. American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987, 136:225-244.
8. British Thoracic Society Guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997, 52:S1-S28.
9. McEvoy C.E., Ensrud K.E., Bender E., Genant H.K., Yu W., Griffith J.M., et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:704-709.
10. Henzen C., Suter A., Lerch E., Urbinelli R., Schorno X.H., Briner V.A. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000, 355:542-545.
11. Mitchell C.E., Alpers J.H., Morton S.M., Baggoley C.J., Croker W.D., Walsh A.J., et al. Comparison of nebulized budesonide with oral prednisolone in the treatment of severe acute asthma. Eur Respir J 1995, 8:S490. (abstract).
12. Maltais F., Ostinelli J., Bourbeau J., Tonnel A.B., Jacquemet N., Haddon J., et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002, 165:698-703.
13. Vestbo J., Hurd S.S., Agustí A.G., Jones P.W., Vogelmeier C., Anzueto A., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 15, 187(4):347-365.
14. Gaude G.S., Nadagouda S. Nebulized corticosteroids in the management of acute exacerbation of COPD. Lung India 2010, 27(4):230-235.
15. Niewoehner D.E., Erbland M.L., Deupree R.H., Collins D., Gross N.J., Light R.W., et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. NEngl J Med 1999, 340:1941-1947.
16. Davies L., Angus R.M., Calverley P.M.A. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999, 354:456-460.
17. Thompson W.H., Nielson C.P., Carvalho P., Charan N.B., Crowley J.J. Con-trolled trial of oral prednisone in outpatients with acute COPD exac-erbation. Am J Respir Crit Care Med 1996, 154:407-412.
18. Mirici A., Meral M., Akgun M. Comparison of the efficacy of nebulised budesonide with parenteral corticosteroids in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Clin Drug Invest 2003, 23:55-62.
19. Barnes P.J. Glucocorticosteroids:current and future directions. Br J Pharmacol 2011, 163(1):29-43.
20. Mercado N., To Y., Ito K., Barnes P.J. Nortriptyline reverse corticosteroid insensitivity by inhibition of phosphoinositide-3-kinase-δ. JPharmacol Exp Ther 2011, 337(2):465-470.